DoriVac DNA vaccine matches mRNA, skips cold chain
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- DoriVac is a DNA origami vaccine platform developed by a multidisciplinary team at Harvard's Wyss Institute, Dana-Farber Cancer Institute, and partner institutions, designed as both a vaccine and self-contained adjuvant built from self-assembling square DNA nanostructures.
- Researchers targeted a conserved HR2 peptide region in viral spike proteins, and the DoriVac vaccines triggered strong antibody-driven (humoral) and T cell-driven (cellular) immune responses in mice against SARS-CoV-2, HIV, and Ebola targets.
- The Wyss Institute's human lymph node-on-a-chip (Organ Chip) platform showed the SARS-CoV-2-HR2 DoriVac vaccine activated human dendritic cells and significantly increased inflammatory cytokine production, along with CD4+ and CD8+ T cells with multiple protective functions.
- DoriVac matched a Moderna/Pfizer mRNA-LNP vaccine encoding the same SARS-CoV-2 spike protein in producing antiviral T cell and antibody-producing B cell responses in mice, but avoided the cold-chain storage and complex lipid nanoparticle manufacturing that constrain mRNA vaccines.
- The study, co-led by Wyss Core Faculty member William Shih, Ph.D., and first/corresponding author Yang (Claire) Zeng, M.D., Ph.D., was published in Nature Biomedical Engineering and was funded by the Wyss Director's Fund, NIH (U54 CA244726-01), and others.
- Zeng has co-founded DoriNano to translate the platform toward clinical use, and the company has reported a promising safety profile in recent studies, though the vaccine has not yet entered human clinical trials.
Why it matters: If DoriVac's preclinical results hold in human trials, its lack of cold-chain requirements and simpler manufacturing could remove the distribution barriers that have limited mRNA vaccine access in low-resource regions — potentially expanding future COVID-19, HIV, and Ebola vaccine availability where infrastructure is weakest. The mRNA match in efficacy is the headline; the logistics gap is the actual public-health story.
